waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.

Zinzani, Pier LuigiMayer, JiriBenjamini, OhadBerkovits, AlejandroGlimelius, IngridStevens, Don A.Chaudhry, Arvind2024-06-122024-06-1220230732-183X1527-7755https://hdl.handle.net/20.500.14551/26792Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 02-06, 2023 -- Chicago, IL[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.Conference Object4116N/AWOS:001053772005460